Search Results - Krish Patel
- Showing 1 - 19 results of 19
-
1
-
2
-
3
-
4
-
5
-
6
-
7
Cumulative review of hypertension in patients with chronic lymphocytic leukemia treated with acalabrutinib by Alessandra Ferrajoli, George Follows, Yotvat Marmor, Jack Roos, Naghmana Bajwa, Venkata Madhira, Kenji Nozaki, Paulo Miranda, Dinci Pennap, Krish Patel
Published in Haematologica (2024-11-01)Get full text
Article -
8
Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naive or relapsed / refractory mantle cell lymphoma: phase Ib trial by Tycel Phillips, Michael Wang, Tadeusz Robak, David Gallinson, Don Stevens, Krish Patel, Safaa Ramadan, Chuan-Chuan Wun, Wojciech Jurczak, Stephen D. Smith
Published in Haematologica (2024-09-01)Get full text
Article -
9
P1094: SAFETY AND EFFICACY OF ACALABRUTINIB, BENDAMUSTINE, AND RITUXIMAB IN PATIENTS WITH TREATMENT-NAIVE OR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: PHASE IB TRIAL by Tycel Phillips, Michael Wang, Tadeusz Robak, David Gallinson, Don Stevens, Krish Patel, Safaa Ramadan, Chuan-Chaun Wun, Wojciech Jurczak, Stephen D. Smith
Published in HemaSphere (2023-08-01)Get full text
Article -
10
P1112: PATIENT-REPORTED OUTCOMES (PRO) AMONG PATIENTS WITH MANTLE CELL LYMPHOMA RECEIVING PIRTOBRUTINIB AFTER PRIOR COVALENT BTKI: INTERIM PRO ANALYSIS FROM THE BRUIN PHASE 1/2 STU... by Jonathon Cohen, Lindsey Roeker, Chan Cheah, Toby Eyre, Krish Patel, Jennifer Woyach, John Seymour, Michael Wang, Yucai Wang, Angely Loubert, Nalin Payakachat, Lisa Hess, Paolo Abada, Anthony R. Mato, Paolo Ghia
Published in HemaSphere (2023-08-01)Get full text
Article -
11
P1200: ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): UPDATED RESULTS FROM THE PHASE 1 WAVELINE-001 STUDY by Stephen Spurgeon, Matthew Mei, Paul M. Barr, Jacqueline Barrientos, Sven de Vos, Richard Furman, Krish Patel, Philip Thompson, Michael Y. Choi, Avyakta Kallam, Siruo Wang, Uzor Ogbu, Patricia Marinello, Michael Wang
Published in HemaSphere (2023-08-01)Get full text
Article -
12
P618: LONG-TERM SAFETY WITH ≥12 MONTHS OF PIRTOBRUTINIB IN RELAPSED/REFRACTORY (R/R) B-CELL MALIGNANCIES by Wojciech Jurczak, Catherine C. Coombs, Nirav N. Shah, Jennifer Woyach, Chan Y. Cheah, Krish Patel, Kami Maddocks, Yucai Wang, Catherine E. Muehlenbein, Chunxiao Wang, Sarang Abhyankar, Donald E. Tsai, Toby A. Eyre
Published in HemaSphere (2023-08-01)Get full text
Article -
13
P1087: PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS AND SUBGROUP ANALYSIS FROM THE PHASE 1/2 BRUIN STUDY WITH >3 YEARS FOLLOW-UP FROM S... by Wojciech Jurczak, Pier Luigi Zinzani, Toby A. Eyre, Chan Y. Cheah, Chaitra S. Ujjani, Koji Izutsu, Shuo MA, Ian Flinn, Alvaro J. Alencar, David Lewis, Krish Patel, Kami Maddocks, Yucai Wang, Talha Munir, Andrew D. Zelenetz, Minna Balbas, Donald E. Tsai, Chunxiao Wang, Michael L. Wang, Nirav N. Shah
Published in HemaSphere (2023-08-01)Get full text
Article -
14
Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies by John N. Allan, Javier Pinilla-Ibarz, Douglas E. Gladstone, Krish Patel, Jeff P. Sharman, William G. Wierda, Michael Y. Choi, Susan M. O’Brien, Mazyar Shadman, Matthew S. Davids, John M. Pagel, Habte A. Yimer, Renee Ward, Gary Acton, Pietro Taverna, Daniel L. Combs, Judith A. Fox, Richard R. Furman, Jennifer R. Brown
Published in Haematologica (2021-12-01)Get full text
Article -
15
Opioid overdose and cardiovascular disease-related mortality: a retrospective analysis using real-world data from the USA, 1999–2023 by Mohamed Fawzi Hemida, Alyaa Ahmed Ibrahim, Maryam Saghir, Ahmed Elshahat, Mohammad Rayyan Faisal, Moaz Elsayed Abouelmagd, Zeyad Kholeif, Krish Patel, Noha Hammad, Pakeezah Tabasum, Eshal Saghir, Mohammed Hammad Jaber Amin, Ahmed Elmorsy Mohamed, Khaled Ali, Basel Abdelazeem, Mustafa Al-jarshawi, Mustafa Al-jarshawi, Mustafa Al-jarshawi, Mustafa Al-jarshawi, Mustafa Al-jarshawi
Published in Frontiers in Cardiovascular Medicine (2026-05-01)Get full text
Article -
16
S146: GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR (CBTKI) PRE-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: RESULTS FROM THE PHASE I/II BRUIN... by Jennifer R. Brown, Sai Prasad Desikan, Bastien Nguyen, Helen Won, Shady Tantawy, Samuel Clark Mcneely, Narasimha Marella, Kevin Ebata, Jennifer Woyach, Krish Patel, Constantine Tam, Toby Eyre, Chan Cheah, Nirav N Shah, Paolo Ghia, Wojciech Jurczak, Minna Balbas, Binoj Nair, Paolo Abada, Chunxiao Wang, Denise Wang, Anthony R. Mato, Varsha Gandhi, William G. Wierda
Published in HemaSphere (2023-08-01)Get full text
Article -
17
Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers by Timothy J. Voorhees, Eric M. McLaughlin, Pallawi Torka, Jorge Florindez, Na Hyun Kim, Tamara K. Moyo, Heather Reves, Nuttavut Sumransub, Saarang Deshpande, Ashley Rose, Cassandra Duarte, Muhammad Salman Faisal, Showkat Hamid, Suki Subbiah, Sabarish Ayyappan, Lauren Shea, Matt Cortese, Krish Patel, Ajay Major, Hayder Saeed, Jakub Svoboda, Sanjal Desai, Praveen Ramakrishnan Geethakumari, Mehdi Hamadani, Natalie Grover, Narendranath Epperla
Published in Blood Cancer Journal (2025-03-01)Get full text
Article -
18
P1108: EFFICACY OF PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA: RESULTS FROM THE PHASE 1/2 BRUIN... by Lydia Scarfò, Manish R. Patel, Toby A. Eyre, Wojciech Jurczak, David Lewis, Thomas Gastinne, Shuo MA, Jonathon B. Cohen, Krish Patel, Jennifer R. Brown, Talha Munir, Ewa Lech-Maranda, Marc S. Hoffmann, Chaitra S. Ujjani, Bita Fakhri, Michael Wang, Koji Izutsu, Hirokazu Nagai, Constantine S. Tam, John F. Seymour, Joanna Rhodes, Julie Vose, Matthew Mckinney, James N. Gerson, Minal A. Barve, Bryone Kuss, Youngil Koh, Wei Gao, Amy S. Ruppert, Richard A. Walgren, Donald E. Tsai, Binoj Nair, Katherine Bao, Anthony R. Mato, Chan Y. Cheah, M Lia Palomba
Published in HemaSphere (2023-08-01)Get full text
Article -
19
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial by Nirav N. Shah, Michael Wang, Lindsey E. Roeker, Krish Patel, Jennifer A. Woyach, William G. Wierda, Chaitra S. Ujjani, Toby A. Eyre, Pier Luigi Z inzani, Alvaro J. Alencar, Paolo Ghia, Nicole Lamanna, Marc S. Hoffmann, Manish R. Patel, Ian Flinn, James N. Gerson, Shuo Ma, Catherine C. Coombs, Chan Y. Cheah, Ewa Lech-Maranda, Bita Fakhri, Won Seog Kim, Minal A. Barve, Jonathon B. Cohen, Wojciech Jurczak, Talha Munir, Meghan C. Thompson, Donald E. Tsai, Katherine Bao, Nicholas A. Cangemi, Jennifer F. Kherani, Richard A. Walgren, Hongmei Han, Amy S. Ruppert, Jennifer R. Brown
Published in Haematologica (2024-10-01)Get full text
Article
